{
    "clinical_study": {
        "@rank": "48775", 
        "arm_group": [
            {
                "arm_group_label": "Trivalent virosomal influenza vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Trivalent virosomal influenza vaccine will be administered intramuscularly (injection of a substance into a muscle) on Day 1 in healthy participants."
            }, 
            {
                "arm_group_label": "Commercial vaccine 1", 
                "arm_group_type": "Active Comparator", 
                "description": "Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants."
            }, 
            {
                "arm_group_label": "Quadrivalent virosomal influenza vaccine", 
                "arm_group_type": "Experimental", 
                "description": "Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants."
            }, 
            {
                "arm_group_label": "Commercial vaccine 2", 
                "arm_group_type": "Active Comparator", 
                "description": "Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to examine the safety and tolerability  after administration of\n      trivalent and quadrivalent cell-based virosomal influenza vaccine in healthy adults."
        }, 
        "brief_title": "Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy Adults", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind and randomized study in healthy adults. The duration of study will be\n      approximately 90 days per participant. The study will include 4 visits: Day 1 (for\n      vaccination), Day 4, Day 22 and day 90 (Follow-up visits). Safety and tolerability will be\n      assessed by the rate of solicited, unsolicited, and serious adverse events."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male or female adults\n\n          -  Body Mass Index <= 30 kilogram per square meter (kg/m^2)\n\n          -  Written informed consent\n\n        Exclusion Criteria:\n\n          -  Vaccination with 2013/2014-seasonal influenza vaccine and/or receipt of any vaccine\n             in the 4 weeks preceding receipt of study vaccine and/or any vaccination planned\n             within 3 weeks from the study vaccine\n\n          -  Diagnosis (by rapid test, performed at clinic/hospital laboratory) of\n             laboratory-confirmed influenza in the 2013/2014 season\n\n          -  Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or\n             other acute disease\n\n          -  Acute febrile illness (greater than or equal to 38.0 celcius)\n\n          -  Pregnancy as assessed by urine pregnancy test before vaccination, or lactation. Women\n             of childbearing potential (that is, not surgically sterilized/hysterectomized or\n             post-menopausal for more than 2 years) will be excluded if one of the following\n             criteria is met: 1). Intention to become pregnant during the course of the study or\n             to donate eggs (ova, oocytes) for the purposes of assisted reproduction 2). If\n             heterosexually active, not using or not willing to continue using a medically\n             reliable method of contraception for the entire study duration (up to 90 days). A\n             medically reliable method of contraception includes oral contraceptive preparation\n             (for example pills), hormonal implant, progestative injection, patch contraceptive\n             formulation, an intrauterine device, concomitant use of barrier method and\n             spermicide, or another method considered sufficiently reliable by the investigator in\n             individual cases"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "49 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02148328", 
            "org_study_id": "CR104114", 
            "secondary_id": [
                "FLUCELLFLZ1003", 
                "2014-000573-39"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Trivalent virosomal influenza vaccine", 
                "description": "Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.", 
                "intervention_name": "Trivalent virosomal influenza vaccine", 
                "intervention_type": "Biological", 
                "other_name": "Trivalent FluCell"
            }, 
            {
                "arm_group_label": "Commercial vaccine 1", 
                "description": "Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.", 
                "intervention_name": "Commercial vaccine 1", 
                "intervention_type": "Biological", 
                "other_name": "Inflexal V (trivalent)"
            }, 
            {
                "arm_group_label": "Quadrivalent virosomal influenza vaccine", 
                "description": "Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.", 
                "intervention_name": "Quadrivalent virosomal influenza  vaccine", 
                "intervention_type": "Biological", 
                "other_name": "Quadrivalent FluCell"
            }, 
            {
                "arm_group_label": "Commercial vaccine 2", 
                "description": "Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.", 
                "intervention_name": "Commercial vaccine 2", 
                "intervention_type": "Biological", 
                "other_name": "Fluarix Tetra (quadrivalent)"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Healthy participants", 
            "Immunogenicity", 
            "Influenza", 
            "Prevention", 
            "Safety"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Phase 1, Double-blind, Active-controlled, Randomized Study in Healthy Adults to Evaluate Safety, Tolerability, and Immunogenicity of a Trivalent and Quadrivalent Cell-based Virosomal Subunit Influenza Vaccine", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "This study is not yet recruiting patients. Please check back for future recruiting sites, or email"
        }, 
        "overall_official": {
            "affiliation": "Crucell Holland BV", 
            "last_name": "Crucell Holland BV Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The local AEs pain, erythema, and induration at the study vaccine injection site will be noted in the participant Diary from Day 1 to Day 8. The extent (largest diameter) of any redness or induration should be measured daily and recorded, along with any functional limitation of activity. Local AEs will be graded according to severity as mild (Grade 1), moderate (Grade 2), severe (Grade 3) and potentially life threatening (Grade 4).", 
                "measure": "Number of participants with Solicited Local Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 8"
            }, 
            {
                "description": "The solicited systemic AEs headache, fatigue, myalgia, malaise, and shivering/rigors will be noted in the participant Diary from Day 1 to Day 8. Fever (defined as body temperature greater than 38.0 Celsius) is another solicited systemic AE. Local AEs will be graded according to severity as mild (grade 1), moderate (grade 2), severe (grade 3) and potentially life threatening (grade 4).", 
                "measure": "Number of participants with Solicited Systemic Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 8"
            }, 
            {
                "description": "Unsolicited AEs are all AEs the participants are not specifically asked about in the participant Diary.", 
                "measure": "Number of participants with Unsolicited Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 22"
            }, 
            {
                "description": "The SAE is a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization or is a suspected transmission of any infectious agent via medicinal product.", 
                "measure": "Number of participants with Serious Adverse Events (SAEs)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 90"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02148328"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants with seroconversion will be the participants with a greater than or equal to (>=) 4-fold increase in hemagglutination inhibition (HI) antibody titer and a titer of >=1:40 at Day 22. HI against homologous strains will be measured with the HI test in serum.", 
                "measure": "Number of Participants with Seroconversion", 
                "safety_issue": "No", 
                "time_frame": "Day 22"
            }, 
            {
                "description": "Number of participants with seroprotection is defined as number of participants with HI antibody >=1:40 at Day 22. HI against homologous strains will be measured with the HI test in serum.", 
                "measure": "Number of Participants with Seroprotection", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 22"
            }, 
            {
                "description": "GMT and increase in GMT of HI antibodies from Baseline to Day 22 will be assessed.", 
                "measure": "Change From Baseline in Geometric Mean Titer (GMT) of HI antibodies", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Day 22"
            }
        ], 
        "source": "Crucell Holland BV", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Crucell Holland BV", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}